Drug intelligence / Profile preview

JD003

Development stage: Preclinical
Lead developer: Beijing Jingda Biotechnology
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

JD003 is an investigational chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by Jingda Biotechnology for the treatment of multiple myeloma. The therapy utilizes engineered natural killer cells designed to target and eliminate malignant plasma cells associated with multiple myeloma. JD003 is currently in the discovery stage of development.

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on JD003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JD003.

Explore the full profile